Pdp (68071 3846 3)
Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-3846
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-3846). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nucare Pharmaceuticals.inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Spl Image1 Structure1)
Figure 1 (Spl Image2 Figure1)
This text provides information on a comparison between Atenolol and Losartan Potassium in terms of their effect on the primary endpoint in patients. It indicates an adjusted risk reduction of 13% with a significance level of p=0.021. The timeline mentioned shows the study months from 0 to 66.*
Figure 2 (Spl Image3 Figure2)
This text provides information on the comparison between Atenolol and Losartan Potassium in terms of adjusted risk reduction, with a 25% reduction demonstrated and a p-value of 0.001. It also shows the percentage of patients with fatal/non-fatal stroke at different study months.*
Figure 3 (Spl Image4 Figure3)
The text describes the primary endpoint events within different demographic subgroups in a study comparing Losartan Potassium with Atenolol in patients. The subgroups include age, gender, race, presence of isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). The results are presented in terms of rate of stroke events and hazard ratios with confidence intervals. Additionally, the text clarifies that "Other" in race includes various ethnic backgrounds like Asian, Hispanic, Multi-race, Indian, Native American, and European. The analysis is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 (Spl Image5 Figure4)
This text presents data on the percentage of patients experiencing an event in a study involving Losartan Potassium versus Placebo over a span of 48 months. The risk reduction rate is calculated at 16.1% with a significance level of p=0.022.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
